Entera Bio Prices $275M Oversubscribed Private Placement at $2.04 Per Share, Closing Expected July 28

Entera Bio Ltd. (NASDAQ: ENTX) priced a $275 million private placement on July 27, 2026 — a raise that dwarfs the company's $101.0 million market capitalization as of that same date and is expected to fund its lead drug through a Phase 3 trial and NDA submission.

The company entered into a securities purchase agreement to issue 122,961,215 ordinary shares and pre-funded warrants to purchase up to an additional 11,842,695 ordinary shares, all at a purchase price of $2.04 per share, per the July 27, 2026 announcement on GlobeNewswire. The pre-funded warrants carry an exercise price of NIS 0.0000769 per share, are immediately exercisable, and carry no expiration date. Closing is expected on or about July 28, 2026, subject to customary closing conditions.

The placement was oversubscribed and led by existing investor BVF Partners L.P. New participants include Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, and RA Capital Management. Upon closing, BVF gains the right to designate two directors to Entera's board, subject to standard eligibility requirements.

Entera said net proceeds, combined with existing cash and cash equivalents, are expected to extend the company's cash runway into 2030. The company's stated use of proceeds is threefold: fully fund Phase 3 registrational studies and a planned NDA submission for EB613 in osteoporosis; advance EB612 into Phase 1 for hypoparathyroidism in collaboration with OPKO Health; and support working capital and general corporate purposes.

EB613 is described by Entera as the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis.

The financing lands against a lean operating baseline. Entera generated $42,000 in revenue in FY2025, posted operating income of -$11.5 million, and produced -$7.4 million in operating cash flow, per data as of July 27, 2026. With approximately 49.3 million shares outstanding before this transaction, the 122,961,215 new ordinary shares represent a substantial dilution event — though the cash runway extension to 2030 is the company's stated rationale for the size of the raise.

Shares jumped 44.5% on July 27, 2026 following the announcement, per Investing.com.

No executive quote was available in the source materials reviewed.

Next steps disclosed by the company: closing of the placement on or about July 28, 2026, followed by initiation of Phase 3 registrational work for EB613 and the Phase 1 advancement of EB612 in collaboration with OPKO Health.